FIELD: medicine; pharmaceuticals.
SUBSTANCE: invention relates to pharmaceutical industry and is a use of (tetrahydropyran-4-yl)-[2-phenyl-5-(1,1-dioxo-thiomorpholin-4-yl)methyl-1H-indol-7-yl]-amine or a pharmaceutically acceptable salt thereof for the preparation of a medicament for preventing or treating of non-alcoholic steatohepatitis, where non-alcoholic steatohepatitis is caused by the fat accumulation in the liver and oxidative stress or inflammatory cytokines derived from fatty liver.
EFFECT: invention provides effectively preventing or treating non-alcoholic steatohepatitis, where non-alcoholic steatohepatitis is caused by fat accumulation in the liver and oxidative stress or inflammatory cytokines derived from fatty liver.
1 cl, 5 dwg, 2 ex
| Title | Year | Author | Number |
|---|---|---|---|
| NEW COMPOUNDS AND PHARMACEUTICAL COMPOSITION CONTAINING THEM | 2019 |
|
RU2793138C2 |
| NOVEL PHARMACEUTICAL USE OF THIENO[3,2-D]PYRIMIDIN-4-ONE COMPOUNDS | 2019 |
|
RU2768828C1 |
| THERAPEUTIC AGENT FOR LIVER DISEASES | 2018 |
|
RU2723686C1 |
| USING LACTITOL AND AN ORAL DOSAGE FORM FOR TREATING AND PREVENTING NON-ALCOHOLIC FATTY LIVER DISEASE | 2018 |
|
RU2692243C1 |
| METHOD FOR DIFFERENTIAL DIAGNOSIS OF LIVER STEATOSIS AND NON-ALCOHOLIC STEATOHEPATITIS IN MEN | 2020 |
|
RU2753455C1 |
| TREATMENT OF NON-ALCOHOLIC FATTY LIVER DISEASE | 2019 |
|
RU2815647C2 |
| PHARMACEUTICAL COMPOSITION, CONTAINING INDOLE COMPOUND | 2010 |
|
RU2557243C2 |
| PYRIDINE SULFONAMIDE COMPOUNDS FOR THE TREATMENT OF CONDITIONS ASSOCIATED WITH INTERLEUKIN 1 BETA | 2019 |
|
RU2803242C2 |
| PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING NON-ALCOHOLIC FATTY LIVER INFILTRATION, CONTAINING GPR119 LIGAND AS ACTIVE INGREDIENT | 2019 |
|
RU2768943C1 |
| KIT FOR PREDICTION OR DIAGNOSTICS OF NON-ALCOHOLIC FATTY LIVER DISEASE AND A METHOD OF DIAGNOSTICS OF NON-ALCOHOLIC FATTY LIVER DISEASE | 2020 |
|
RU2800086C1 |
